New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative ...

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS MASITINIB PLATFORMParis, January 29, 2025, 7pm CETAB Science SA (Euronext - FR0010557264 - AB) ...

Able to cross the blood-brain barrier, Xenon gas seemed to perk the mice right up, which began to become particularly active ...

The agreement will allow Enigma to use its PET imaging tracer PMI04 to visualize microglia activity in neurodegenerative ...

Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...

An inert and unreactive gas may not seem like an obvious candidate for treating Alzheimer's disease, yet a new study in mice ...

An inert and unreactive gas may not seem like an obvious candidate for treating Alzheimer's disease, yet a new study in mice suggests that xenon ...

Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...

Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® ...